Kymera Therapeutics Inc
NASDAQ: KYMR · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Kymera Therapeutics Inc (KYMR) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-17.86M | $17.91M | $88.13M | $-128.95M | $-153.09M | $-102.83M | $-194.50M | $-232.89M |
| Capital expenditures | $1.36M | $532000.00 | $9.10M | $1.60M | $2.84M | $34.48M | $12.84M | $1.45M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $648000.00 | $1.20M | $5.19M | $24.97M | $35.48M | $43.12M | $55.01M | $59.90M |
| Free cash flow | $-19.22M | $17.37M | $79.03M | $-130.54M | $-155.92M | $-137.31M | $-207.34M | $-234.34M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $-45.20M | $21.50M | $20.43M | — | — | — |
Frequently asked questions
What is Kymera Therapeutics Inc's revenue?
Kymera Therapeutics Inc's trailing twelve-month revenue is $51.48M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is KYMR?
In its most recent fiscal year, KYMR ran a gross margin of 100.00%, an operating margin of -891.33%, and a net margin of -794.39%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does KYMR generate?
KYMR produced $-234.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KYMR's balance sheet healthy?
KYMR holds $357.01M in cash and equivalents against — in long-term debt, on $1.58B of shareholder equity. That debt is best read against the cash flow the business throws off each year.